Jynarque 90MG-30MG
Ended Awarded
- Contract number
- 36C24525N0313
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $13,168
Award facts
- Contract value 100% obligated
- $13,168.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc., a specialty pharmaceutical manufacturer headquartered in Rockville, Maryland, received a delivery order award from the Department of Veterans Affairs Veterans Integrated Service Network 5 on January 14, 2025, for the supply of Jynarque (tolvaptan) 90mg-30mg tablets. This firm-fixed-price delivery order, valued at $13,168.39, is expected to be completed by January 17, 2025, and will be delivered to VA facilities in Pittsburgh, Pennsylvania. The award does not utilize any set-aside designation, reflecting Otsuka America's established status as a large pharmaceutical manufacturer within the federal marketplace.
This delivery order is issued under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents a task order against Otsuka America's larger Blanket Purchase Agreement with the VA's National Acquisition Center, valued at $83.3 million with a completion date of March 26, 2026. Jynarque is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veterans. Through this established indefinite delivery vehicle, the VA streamlines procurement of critical pharmaceutical treatments across multiple Integrated Service Networks nationwide, enabling efficient access to this specialty medication for eligible veterans requiring treatment.
Quick answers
Who was awarded contract 36C24525N0313?
36C24525N0313 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on January 14, 2025.
How much is contract 36C24525N0313 worth?
The government has obligated $13,168 on 36C24525N0313.
Is contract 36C24525N0313 an order under another contract?
Yes. 36C24525N0313 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24525N0313 competed?
The extent of competition for 36C24525N0313 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award